Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

s.  The Phase 2 clinical trial is designed as a 12-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX2931 and its effects on symptoms associated with rheumatoid arthritis. With enrollment in the study proceeding ahead of schedule, the Company has filed for regulatory authorization to permit enrollment of up to 200 patients, an increase from the originally-planned enrollment of up to 120 patients, which will increase the likelihood of observing a positive statistical trend. The study is being conducted at multiple centers in the United States and Eastern Europe.  Top-line data from the expanded trial are expected to be available around the end of the year.
  • Lexicon continues to enroll patients in a Phase 2a study of its drug candidate for carcinoid syndrome, LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.  The Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome.  The study is expected to include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy.  Top-line data from the trial are expected to be available in the secon
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
    8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
    9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
    10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
    11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... (PRWEB) February 27, 2015 The ... system (Nexera UC) can sequentially analyze up to ... combined with high-sensitivity detection of targets by mass ... designed to fulfill the measurement requirements of a ... food products, drug delivery and search for disease ...
    (Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
    (Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... for judgment notwithstanding the verdict, a new trial, and ...
    (Date:2/26/2015)... LA JOLLA, Calif. , Feb. 26, 2015 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D., President and Chief Executive ... the Cowen and Company 35 th Annual Healthcare ... EST.  The conference is being held at the Boston ...
    Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
    ... with YWCA & Roche to Educate Patients on, ... and a Career -, NEW YORK, March 10 ... Careers, a non-profit program,founded by Cosmetic Executive Women Foundation, ... the hundreds of thousands of people,living with cancer on ...
    ... J.D., joins BrainCells, Board of ... ... (BCI), a,biopharmaceutical company utilizing its platform technology to identify and,develop compounds ... nervous system (CNS) diseases, announced today that it has,completed a $30 ...
    ... CITY, Calif., March 10, Otsuka Pharmaceutical Co., Ltd. ... today announced the closing of the,previously announced transaction ... Busulfex(R) (busulfan), including trademarks, patents,intellectual property and related ... Busulfex is an oncologic product marketed and sold ...
    Cached Biology Technology:First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 2First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 3BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4
    (Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
    (Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
    (Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
    Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
    ... Antibiotic resistance is a growing human health concern. ... other pharmaceuticals to be present in surface waters ... underlying groundwater. In a recent article in the ... at Colorado State University (CSU) describe a study ...
    ... potential risks growing" If so, who or ... newswiresenvironmental and consumer organizations, scientists, law makers, or ... decide to cover a nanotechnology story, especially one ... correspondents face special challenges reporting on a technology ...
    ... Antarctica, Nov. 28, 2007 -- A second season in ... exceeded all expectations, according to the co-chief scientists of ... (Nov. 21), the drilling team passed the 1,000-meter mark ... in McMurdo Sound, and with a remarkable recovery rate ...
    Cached Biology News:Manure management reduces levels of antibiotics and antibiotic resistance genes 2Nanotechnology and the media: The inside story 2ANDRILL's 2nd Antarctic drilling season exceeds all expectations 2ANDRILL's 2nd Antarctic drilling season exceeds all expectations 3
    Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
    CBF-B (G-2)...
    HSV-2 gD (0191)...
    ... Dynabeads Epoxy (4.5 m). Hydrophobic naked ... Ideal for coupling of antibodies for cell ... coupling with covalent binding of primary amine ... (SH)) occurring within 16-20 hours. Coupling reactions ...
    Biology Products: